Table 1.
Baseline characteristics of patients with hepatocellular carcinoma treated with transarterial chemoembolization.
| mRECIST categories | p value | ||||
|---|---|---|---|---|---|
| Complete (N = 102) |
Partial (N = 138) |
Stable (N = 63) |
Progressive (N = 14) |
||
| Age (mean ± SD) | 61.5 ± 8.7 | 61.5 ± 10.1 | 63.1 ± 9.5 | 61.9 ± 8.3 | 0.697 |
|
| |||||
| Gender | |||||
| Female | 73 (71.6%) | 110 (79.7%) | 40 (71.4%) | 10 (63.5%) | 0.102 |
| Male | 29 (28.4%) | 28 (20.3%) | 23 (28.6%) | 4 (36.5%) | |
|
| |||||
| Race | |||||
| White | 78 (76.5%) | 105 (76.1%) | 43 (68.3%) | 7 (50.0%) | 0.064 |
| Black | 18 (17.7%) | 30 (21.7%) | 13 (20.6%) | 6 (42.9%) | |
| Other | 6 (5.8%) | 3 (2.2%) | 7 (11.1%) | 1 (7.1%) | |
|
| |||||
| Etiology | |||||
| Alcohol | 29 (28.4%) | 35 (25.4%) | 13 (21.0%) | 2 (14.3%) | 0.563 |
| HBV | 7 (6.9%) | 6 (4.4%) | 5 (7.9%) | 2 (14.3%) | 0.434 |
| HCV | 57 (55.9%) | 73 (52.9%) | 21 (33.9%) | 5 (35.7%) | 0.024 |
| NASH | 22 (21.6%) | 28 (20.3%) | 10 (15.9%) | 1 (7.1%) | 0.402 |
|
| |||||
| Child-Pugh class | 0.525 | ||||
| A | 35 (34.3%) | 53 (38.4%) | 28 (44.4%) | 7 (50.0%) | |
| B | 54 (52.9%) | 74 (53.6%) | 28 (44.4%) | 7 (50.0%) | |
| C | 13 (12.8%) | 11 (8.0%) | 7 (11.2%) | 0 (0.0%) | |
|
| |||||
| AFP∗ | 12.3 ± 100.8 | 22.0 ± 158.9 | 27.0 ± 132.6 | 132.0 ± 3601.0 | 0.179∗∗ |
|
| |||||
| Diameter of largest tumor | 3.6 ± 1.8 | 4.6 ± 2.5 | 5.6 ± 4.4 | 6.1 ± 3.7 | <0.0001 |
|
| |||||
| Number of tumors | 1.6 ± 0.8 | 1.5 ± 1.0 | 2.1 ± 1.4 | 1.9 ± 1.6 | 0.003 |
∗Medians and interquartile range reported.
∗∗Kruskal-Wallis procedure used.
TACE: transarterial chemoembolization; mRECIST: modified Response Evaluation Criteria In Solid Tumors, p value: probability, SD: standard deviation, HBV: hepatitis B virus, HCV: hepatitis C virus, NASH: nonalcoholic steatohepatitis, and AFP: alpha fetoprotein.